Suneva's product portfolio consists of minimally invasive solutions, including products that use the body’s restorative capacity in non-surgical outpatient treatment settings to deliver immediate aesthetic results

medical

Suneva Medical has agreed to merge with Viveon Health Acquisition. (Credit: Gerd Altmann from Pixabay)

US-based pure-play regenerative aesthetics company Suneva Medical has entered into a merger agreement with special purpose acquisition company (SPAC) Viveon Health Acquisition in a deal worth around $511m.

Based in San Diego of California, Suneva is involved in the development, manufacturing and commercialisation of novel products for the medical aesthetics market.

The company’s product portfolio consists of minimally invasive solutions, including products that use the body’s restorative capacity in non-surgical outpatient treatment settings to deliver immediate aesthetic results.

Suneva offers Bellafill, which is claimed to be the only approved filler from the US Food and Drug Administration (FDA) to correct nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheeks.

Silhouette Instalift is said to be the first resorbable suture FDA-approved product for cosmetic facial procedures.

The company also offers PlasmaIQ hand-held FDA-cleared plasma energy device for skin rejuvenation, Puregraft fat grafting system, Dermapose all-in-one system to harvest, wash and inject sized fat and Amplifine high-density platelet rich plasma (PRP) gel tube and syringe technology.

Suneva CEO Pat Altavilla said: “We are excited to be partnering with Viveon Health as we step into the next phase of growth as a leader in the regenerative aesthetics sector supporting the needs of physicians and patients seeking proven and validated innovations.

“Our journey to this point has been paved with product innovation and clinical education led by an experienced team that brings a proven track record of sales growth and market development.”

Subject to approval by Suneva’s stockholders, Viveon Health’s stockholders and other customary closing conditions, the proposed business combination is expected to be completed in the first half of this year.

Once the deal concludes, the combined company’s securities are anticipated to be traded on the NYSE under the symbol RNEW.